Zhonghua Jie He He Hu Xi Za Zhi. Potential antiviral therapeutics for 2019 Novel Coronavirus

[tetano]

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004. [Potential antiviral therapeutics for 2019 Novel Coronavirus].

[Article in Chinese; Abstract available in Chinese from the publisher]

Li H¹, Wang YM¹, Xu JY², Cao B¹.
Author information

Abstract

in English, Chinese
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.


KEYWORDS:

2019 novel coronavirus; Antiviral therapy; Infection

PMID: 32164080 DOI: 10.3760/cma.j.issn.1001-0939.2020.03.004